
If you have $1,000 ready to invest, it can still go a long way in building a high-quality portfolio.
But where should you put it next week?
Here are three ASX shares that could be best buys right now according to analysts:
NextDC Ltd (ASX: NXT)
The first ASX share that could be a strong option for a $1,000 investment is NextDC.
It operates data centres that provide the infrastructure required for cloud computing, artificial intelligence (AI), and enterprise workloads. As more businesses shift their operations online and invest in AI capabilities, demand for high-performance data centres continues to grow.
NextDC has been expanding its footprint across Australia and the Asia-Pacific and has built relationships with major cloud providers. It also has a significant pipeline of contracted capacity that is expected to convert into revenue over the coming years.
With demand for digital infrastructure increasing, the company appears well placed to benefit from long-term growth in data usage and AI adoption.
Morgans thinks its shares are undervalued. It currently has a buy rating and $20.50 price target on them.
Pro Medicus Ltd (ASX: PME)
Another ASX share that could be worth considering is Pro Medicus.
This healthcare technology company develops imaging software used by hospitals and radiologists. Its Visage platform allows clinicians to view and analyse medical scans quickly and efficiently.
What sets Pro Medicus apart is its capital-light model and strong margins. The company continues to win large contracts with major healthcare providers, which supports its long-term earnings growth outlook.
As medical imaging volumes increase and healthcare systems adopt more advanced digital tools, Pro Medicus could continue expanding its global footprint. This is especially the case given critical radiologist shortages.
Bell Potter is bullish on the investment opportunity here. It has a buy rating and $240.00 price target on its shares.
Xero Ltd (ASX: XRO)
A final ASX share to consider for the $1,000 investment is Xero.
It provides cloud-based accounting software to small and medium-sized businesses. Xero’s platform helps users manage invoicing, payroll, and financial reporting, making it an essential tool for many businesses.
Xero benefits from a subscription-based model, which generates recurring revenue and supports long-term growth. It also has significant opportunities to expand internationally and increase revenue per user through additional features and services following recent acquisitions.
With digital adoption continuing across small businesses, Xero could remain a key player in the global accounting software market.
UBS is a big fan of the company and recently put a buy rating and $174.00 price target on its shares.
The post The best ASX shares to invest $1,000 in right now appeared first on The Motley Fool Australia.
Should you invest $1,000 in NEXTDC Limited right now?
Before you buy NEXTDC Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and NEXTDC Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why buying ASX shares in March could supercharge your wealth
- Morgans says these ASX 200 shares could rise 120%
- Are these the smartest ASX tech stocks to buy now with $2,000?
- 2 ASX tech shares that could double from here
- 3 ASX healthcare stocks tipped to soar over 100% higher this year
Motley Fool contributor James Mickleboro has positions in Nextdc, Pro Medicus, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.